M U N I Ústav histologie a embryologie



"Achondroplasia Gladiator"— Bibliotheque Nationale, Paris

INTRODUCTION TO TERATOLOGY

Embryology is the study of normal intrauterine embryonic or fetal development.

Teratology is the study of birth defects, and a **teratogen** is something that either induces or amplifies abnormal embryonic or fetal development and causes birth defects.



Historical context

τέρας (Greek) *teras* = monster

Everything looking abnormal



Historical context

Since the 17th century related to abnormal births (development)











- W. Harvey (1578–1657) used the term "developmental arrest",
- C.F. Wolff (1733–1794) in his study on the intestine, the term "germ layer" was coined that has been in use to this day,
- A. von Haller (1708–1777) was first to describe the development of the chicken heart,
- I.G. de Saint-Hillaire (1805–1861) was first to introduce the term "teratology",
- C. Dareste (1822–1899) discussed the modes of artificial induction of monstrosities (particularly by mechanical impulses during icubation of hen eggs),
- R. Virchow (1821–1902) gathered a unique collection of rare developmental disorders of the human body in the "Museum of Pathology" in the Berliner hospital Charité,
- E. Schwalbe (1906–1999) defined the expression "teratogenic termination point",
- **CH.R. Stockard** (1879–1936) introduced the term "critical period".



What is a teratogen?

- X-Rays
- Lipid diet
- Hypovitaminosis
- Sex hormones
- Virus infection
- Chemical substances (NaBr, retinoid
- Drugs (aminopterins, thalidomide, medications)
- Recreational drugs, alcohol
- Environmental pollutant (methyl mercury, agrochemicals)



Teratogens around us

physical ionizing irradiation (UV, RTG, α , β , γ), temperature, mechanical factors (amnion bands, pes equinus, ...)

chemical pharmacological drugs (antibiotics, antiepileptics, anticoagulans, cytostatics) solvents, alcohol, heavy metals, organometals, ...


biological patogens (virus), disease of mother (diabetes, myasthenia gravis, PKU)







How to identify a teratogen?



What does a teratogen do?

Disrupts fine molecular or metabolic pathways

- Intra uterine growth retardation
- Failure of histogenesis, organogenesis
- Embryonic/fetal death




How to identify a teratogen?

- Animal studies
- Observations from human exposure


Koch's Postulates in microbiology:

- The microorganism must be found in abundance in all organisms suffering from the disease, but should not be found in healthy organisms.
- The microorganism must be isolated from a diseased organism and grown in pure culture.
- The cultured microorganism should cause disease when introduced into a healthy organism.
- The microorganism must be reisolated from the inoculated, diseased experimental host and identified as being identical to the original specific causative agent.



"Koch's Postulates" adapted for teratology:

- The agent must be present during the critical stage of development.
- The agent produces a particular pattern of birth defects in animal studies.
- The agent crosses the placenta and there is a dose-response relationship.
- There is an abrupt increase in the frequency of a particular defect (syndrome).
- The increase of defects is associated with the use of a new drug or the to a chemical or environmental change.
- There is an absence of other factors to explain the observations.
- The mechanism of teratogenesis makes biological sense.








Figure 1 Embryotoxicity of LAR in mouse embryo culture. (**A**) Abnormal embryonic development and anomalies were observed in treatment groups from 0.5 to 2 mg/ml of LAR. Representative embryos are presented. Closed arrows represent the normal structures. Open arrows represent the malformed structures, including microencephaly, opened neural tube defects and sacral regression. Magnification \times 25. (**B**) Dose—response curve of LAR on embryo development. The minimum concentration of LAR which resulted in a 50% reduction in relative TMS in the embryos was indicated. n = 10 embryos per each LAR concentration.

Molecular Human Reproduction, Vol.18, No.12 pp. 585-592, 2012 Advanced Access publication on August 19, 2012 doi:10.1093/molehr/gas034



ORIGINAL RESEARCH

Molecular studies of the congenital malformation induced by Largehead Atractylodes Rhizome, the most commonly used Chinese medicine for threatened miscarriage

L.Y. Tangʻi, L. Liʻi, A. Borchert², Clara B.S. Lau³, P.C. Leung³, and C.C. Wangʻi,4,*


Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Price of Wales Hospital, Statis, New Tentrontes, Hong Kong Tentral or Biochemistry, University of Medicine Bertin, Charles, Bertin, Germany Tenstrue of Chinese Medicine, The Chinese University of Hong Kong, Statin, New Tentrontes, Hong Kong "School of Biomedical Sciences, The Chinese University of Hong Kong, Statin, New Tentrontes, Hong Kong "School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, New Tentrontes, Hong Kong Statin, New Tentrontes, Hong Kong, Statin, New Tentrontes, Hong Kong Statin, New Tentrontes, Hong Kong, Statin, New Tentrontes, Hong

*Correspondence address. Tel: +852-2632-2810; Fax: +852-2636-0008; E-mail: ccwang@cuhk.edu.hk Submitted on March 27, 2012; resubmitted on August 3, 2012; accepted on August 9, 2012

How to identify a teratogen?


- Animal studies
- Observations from human exposure

Understand the biological context



Wilson's Six Principles of Teratology (1977)

- 1. Susceptibility to teratogenesis depends on the **genotype** of the conceptus and the way in which this interacts with environmental factors.
 - 2. Susceptibility to teratogenic agents varies with the **developmental stage** at the time of exposure.
 - 3. Teratogenic agents act in **Specific Ways** (mechanisms) on developing cells and tissues to initiate abnormal embryogenesis (pathogenesis).
 - 4. The **final manifestations** of abnormal development are death, malformation, growth retardation, and functional disorder.
- 5. The access of adverse environmental influences to developing tissues depends on the **nature of the influences** (agent).
- 6. Manifestations of deviant development increase in degree as **dosage** increases from the no-effect to the totally lethal level.



Mechanisms of action?

- Mutation
- Chromosomal nondisjunction and breaks Mitotic interference
- Altered nucleic acid integrity or function
- Lack of precursors and substrates needed for biosynthesis
- Altered energy sources
- Enzyme inhibitions
- Osmolar imbalance
- Altered membrane characteristics
- Epigenetic control of gene expression
- The effects of small regulatory RNAs
- The imbalance of gene products resulting from submicroscopic alterations of genomic structure such as copy number changes
- Alterations of the cytoskeleton
- Perturbations of the extracellular matrix
- Effects of mechanical forces on embryogenesis
- Disturbances of intracellular or intercellular signalling
- Dysfunction of molecular chaperones
- Effects on the distribution of molecules into subcellular compartments
- Alterations of the integrity of intracellular organelles

1977

2010

Teratogen	Vrozená vada
Infekce	
rubeola virus	katarakta, glaukom, srdeční vady, hluchota, abnormality zubů
cytomegalovirus	microcephalia, slepota, mentální retardace, odumření fetu
virus Herpes simplex	microphthalmia, microcephalia, retinální dysplasie
virus varicelly	hypoplasie končetin, mentální retardace, svalové atrofie
HIV	microcephalia, růstová retardace
Toxoplasma gondii	hydrocephalia, mozkové kalcifikace, microphthalmia
Treponema pallidum	mentální retardace, hluchota
Fysikální činitelé	
rtg záření	microcephalia, spina bifida, rozštěp patra, defekty končetin
hypertermie	anencephalia, spina bifida, mentální retardace, defekty obličeje srdeční malformace, omphalokéla, defekty končetin
Chemické látky	
thalidomid	defekty končetin, srdeční vady, hluchota, slepota, malformace dalších vnitřních orgánů
aminopterin	anencephalia, hydrocephalia, rozštěp rtu a patra
fenytoin	fetální hydantoinový syndrom, defekty obličeje, mentální retardace
kyselina valproová	defekty nervové trubice, kraniofaciální, srdeční a končetinové vady
trimethadion	rozštěp patra, srdeční, urogenitální a kosterní vady
lithium	srdeční malformace
amfetaminy	rozštěp rtu a patra, srdeční malformace
warfarin	chondrodysplasie, microcephalia
ACE inhibitory	růstová retardace, odumření fetu
kokain	růstová retardace, microcephalia, abnormality chování, gastroschisis
ethanol	fetální alkoholový syndrom, krátké oční štěrbiny, hypoplasie maxily, srdeční malformace, mentální retardace
isotretinoin (analog vitaminu A)	embryopatie vyvolaná vitaminem A: malé abnormálně tvarované uši, mandibulární hypoplasie, rozštěp patra, srdeční vady končetinové vady
průmyslová rozpouštědla	nízká porodní hmotnost, kraniofaciální defekty, defekty nervo vé trubice
organické sloučeniny rtuti	neurologické poruchy připomínající mozkovou obrnu
olovo	růstová retardace, neurologické poruchy

Teratogen	Vrozená vada
Hormony	
androgeny (ethisteron, norethisteron)	maskulinisace ženského zevního genitálu: splynulá labia, hypertrofický klitoris
diethylstilbestrol	hypoplasie varlat, malformace dělohy, vejcovodů a horní části vaginy, v dospělosti karcinom pochvy
diabetes mellitus	řada malformací, hlavně srdečních, defekty nervové trubi- ce, syndrom kaudální regrese spojený s hypoplasií dolních končetin
obesita	srdeční vady, omfalokéla

^{*} ACE – angiotensin-konvertující enzym

- Growth retardation
- Failure of histogenesis, organogenesis
- Embryonic/fetal death

How to classify a teratogen?



https://www.govinfo.gov/content/pkg/FR-2008-05-29/pdf/E8-11806.pdf



https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-exposure-medicinal-products-during-pregnancy-need-post-authorisation-data_en.pdf

Category A: Controlled studies in women fail to demonstrate a risk to the fetus in the first trimester (and there is no evidence of a risk in later trimesters), and the possibility of fetal harm appears remote.

Category B: Either animal-reproduction studies have not demonstrated a fetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the first trimester (and there is no evidence of a risk in later trimesters).

Category C: Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal, or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus.

Category D: There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

Category X: Studies in animals or human beings have demonstrated fetal abnormalities, or there is evidence of fetal risk based on human experience, or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

Further reading

Review Article

Teratogen Screening: State of the Art

Julia Schumann

Faculty of Veterinary Medicine, Institute of Physiological Chemistry, University of Leipzig, Leipzig, Germany

Corresponding author:

Julia Schumann, Ph.D.,
Institute of Physiological
Chemistry, Faculty of
Veterinary Medicine, University
of Leipzig, Leipzig, Germany
Tel: +49 341 9738107
Fax: +49 341 9738119
E-mail:
julia.schumann@vmf.unileipzig.de
Received: 17 Jun 2010

Accepted: 9 Aug 2010

Abstract

Due to the number of new substances coming into use every year and the increasing amounts of chemicals, which are introduced into the environment, there is a high demand for a rapid, reliable and cost-effective method for detection of developmental toxicity. To meet this challenge various *in vitro* techniques have been established additional to *in vivo* animal testing. This review introduces the techniques in existence at the moment. Requirements on an ideal *in vitro* teratogenicity test system are stated, and the advantages and disadvantages of the present methods are discussed.

Avicenna J Med Biotech 2010; 2(3): 115-121

Keywords: Animal testing alternatives, Cell culture techniques, Teratogens






CASE STUDY

Countries and territories showing historical time-line of Zika virus spread (1947 - 2016)





CASE STUDY

Evidence for ZIKV induced microcephaly?



How to identify a new teratogen?

- Observations from human exposure
- <u>Epidemiology</u> Bradford Hill criteria
- <u>Understand the biological context</u> transmission in ecosystem
- Mechanism of action
- Validate on animals

CASE STUDY

Bradford Hill criteria

Formerly published as Medico-Chirurgical Transactions • 1809 – 1907

Proceedings of the Royal Society of Medicine

Now published as Journal of the Royal Society of Medicine • 1978 - current

Proc R Soc Med. 1965 May; 58(5): 295-300.

PMCID: PMC1898525 PMID: <u>14283879</u>



The Environment and Disease: Association or Causation?

Austin Bradford Hill

Strength (effect size): A small association does not mean that there is not a causal effect, though the larger the association, the more likely that it is causal.

Consistency (reproducibility): Consistent findings observed by different persons in different places with different samples strengthens the likelihood of an effect.

Specificity: Causation is likely if there is a very specific population at a specific site and disease with no other likely explanation. The more specific an association between a factor and an effect is, the bigger the probability of a causal relationship.

Temporality: The effect has to occur after the cause (and if there is an expected delay between the cause and expected effect, then the effect must occur after that delay).

Biological gradient: Greater exposure should generally lead to greater incidence of the effect. However, in some cases, the mere presence of the factor can trigger the effect. In other cases, an inverse proportion is observed: greater exposure leads to lower incidence.

Plausibility: A plausible mechanism between cause and effect is helpful (but Hill noted that knowledge of the mechanism is limited by current knowledge).

Coherence: Coherence between epidemiological and laboratory findings increases the likelihood of an effect.


Experiment: "Occasionally it is possible to appeal to experimental evidence".


Analogy: The use of analogies or similarities between the observed association and any other associations.

Reversibility: If the cause is deleted then the effect should disappear as well.


CASE STUDY

ZKV transmission





ZKV mechanism of action



Impaired neurogenesis and microcephaly

CASE STUDY

Validation in animal model

- Failure of placental barrier
- Brain damage



https://www.cidrap.umn.edu/newsperspective/2016/05/animal-studies-detailmarked-zika-damage-developing-brains

Take home message

- Teratology, teratogens → From Koch's postulates to Wilson's principles
- Mechanisms of action → any embryology and/or cell biology textbook
- Classification & clinical examples → any embryology textbook, FDA (EU) categories
- Identification, validation → ZIIKA forest virus story & Bradford Hill criteria

Further reading:

- Friedman JM. The Principles of Teratology: Are They Still True? Birth Defects Research (Part A): Clinical and Molecular Teratology. 2010. 88:766–768.
- Schumann J. Teratogen Screening: State of the Art. Avicenna J Med Biotechnol. 2010. 2(3): 115–121.
- Varga I. Embryology Teaching: An Often-neglected Part of the Medical Curriculum. Rev Arg de Anat Clin.
 2017. 9(2):47-51.
- Ujhazy et al. Teratology past, present and future. Interdiscip Toxicol. 2012. 5(4): 163–168.

Not every genetic anomaly results in a malfunction







RESEARCH

Leaf Trait Coloration in White Clover and Molecular Mapping of the Red Midrib and Leaflet Number Traits

Rebecca M. Tashiro, Yuanhong Han, Maria J. Monteros, Joseph H. Bouton, and Wayne A. Parrott*

Thank you for attention